GSK plc - Company Profile
Powered by 
All the sales intelligence you need on GSK plc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how GSK plc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with GSK plc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreGSK plc (GSK) is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines. The company's major products encompass specialty medicines, vaccines, and general medicines targeting therapeutic areas such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterial, dermatology, and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK’s vaccine portfolio covers various diseases, including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles, and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians, and other groups globally. GSK is headquartered in London, England, the UK.
Headquarters
United Kingdom
Address
79 New Oxford Street, London, England, WC1A1DG
Website
www.gsk.com
Telephone
44 20 80475000
No of Employees
66,841
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GSK (LON)
Revenue (2024)
$43.0B
4.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
122%
(2024 vs 2023)
Market Cap*
$108.8B
Net Profit Margin (2024)
XYZ
113.2%
(2024 vs 2023)
* As of and is in US$
GSK plc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Specialty Medicines | Anoro Ellipta |
| Vaccines | Apretude |
| General Medicines | Arexvy |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed an agreement to acquire Nuvalent Inc, a clinical-stage biopharmaceutical company. |
| 2026 | Regulatory Approval | In June, the company and Spero Therapeutics received approval from the US FDA for Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections, including pyelonephritis1, caused by certain susceptible pathogens2, in adult patients with limited or no alternative oral treatment options. |
| 2026 | Contracts/Agreements | In May, the company entered into a worldwide license agreement with Suzhou Siran Biotechnology Co Ltd for SA030. |
Competitor Comparison
| Key Parameters | GSK plc | Johnson & Johnson | Eli Lilly and Co | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United States of America | United States of America | United States of America | United States of America |
| City | London | New Brunswick | Indianapolis | New York City | North Chicago |
| State/Province | England | New Jersey | Indiana | New York | Illinois |
| No. of Employees | 66,841 | 138,200 | 50,605 | 75,000 | 57,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Luke Victor Miels | Chief Executive Officer; Director | Executive Board | 2026 | 52 |
| Julie Belita Brown | Chief Financial Officer; Director | Executive Board | 2023 | 64 |
| Roanne Parry | Chief People Officer | Senior Management | 2026 | - |
| Tony Wood | Chief Scientific Officer | Senior Management | 2022 | - |
| Shobie Ramakrishnan | Chief Digital and Technology Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer